NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. trimmed its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 63.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,636 shares of the medical research company’s stock after selling 8,048 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in NeoGenomics were worth $64,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. First Light Asset Management LLC boosted its stake in shares of NeoGenomics by 29.6% during the 4th quarter. First Light Asset Management LLC now owns 3,926,756 shares of the medical research company’s stock valued at $63,535,000 after buying an additional 897,843 shares during the period. PNC Financial Services Group Inc. lifted its position in NeoGenomics by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,434 shares of the medical research company’s stock worth $136,000 after acquiring an additional 1,791 shares during the last quarter. Banque Cantonale Vaudoise lifted its position in NeoGenomics by 6.6% during the 1st quarter. Banque Cantonale Vaudoise now owns 15,942 shares of the medical research company’s stock worth $251,000 after acquiring an additional 993 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in NeoGenomics by 9.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,247 shares of the medical research company’s stock worth $334,000 after acquiring an additional 1,791 shares during the last quarter. Finally, Jennison Associates LLC increased its holdings in shares of NeoGenomics by 77.8% during the 1st quarter. Jennison Associates LLC now owns 1,051,627 shares of the medical research company’s stock worth $16,532,000 after purchasing an additional 460,071 shares during the period. 98.50% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on NEO shares. Benchmark restated a “buy” rating and set a $18.00 price objective on shares of NeoGenomics in a report on Tuesday, September 24th. Stephens reissued an “overweight” rating and issued a $19.00 target price on shares of NeoGenomics in a research note on Tuesday, July 30th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a research note on Wednesday, September 25th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, NeoGenomics currently has an average rating of “Moderate Buy” and a consensus price target of $19.89.

NeoGenomics Price Performance

NASDAQ:NEO opened at $13.94 on Friday. The firm has a market cap of $1.78 billion, a PE ratio of -21.12 and a beta of 1.19. NeoGenomics, Inc. has a 12 month low of $11.65 and a 12 month high of $21.22. The company has a quick ratio of 1.93, a current ratio of 2.01 and a debt-to-equity ratio of 0.37. The company’s 50-day moving average price is $15.98 and its two-hundred day moving average price is $14.90.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Monday, July 29th. The medical research company reported $0.03 earnings per share (EPS) for the quarter. NeoGenomics had a negative net margin of 12.50% and a negative return on equity of 2.72%. The company had revenue of $164.50 million for the quarter, compared to analyst estimates of $161.82 million. During the same period in the prior year, the business earned ($0.09) earnings per share. NeoGenomics’s quarterly revenue was up 12.0% on a year-over-year basis. On average, equities analysts anticipate that NeoGenomics, Inc. will post -0.22 EPS for the current fiscal year.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.